Summit TherapeuticsSMMT
SMMT
About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Employees: 159
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 3 (+2) [Q1 2025]
26% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 34
14% more capital invested
Capital invested by funds: $1.65B [Q4 2024] → $1.89B (+$235M) [Q1 2025]
10% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 69
4% more funds holding
Funds holding: 202 [Q4 2024] → 210 (+8) [Q1 2025]
0.69% more ownership
Funds ownership: 12.56% [Q4 2024] → 13.25% (+0.69%) [Q1 2025]
31% less call options, than puts
Call options by funds: $45.5M | Put options by funds: $65.7M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
55%
downside
Avg. target
$33
25%
upside
High target
$44
65%
upside
5 analyst ratings
4 positive
80%
0 neutral
0%
1 negative
20%
UBS David Dai | 12%upside $30 | Buy Initiated | 1 Jul 2025 |
HC Wainwright & Co. Mitchell Kapoor | 65%upside $44 | Buy Reiterated | 1 Jul 2025 |
Leerink Partners Daina Graybosch | 55%downside $12 | Underperform Initiated | 11 Jun 2025 |
JMP Securities Reni Benjamin | 50%upside $40 | Market Outperform Reiterated | 2 Jun 2025 |
Goldman Sachs Salveen Richter | 53%upside $41 | Buy Maintained | 2 May 2025 |
Financial journalist opinion
Based on 16 articles about SMMT published over the past 30 days
Neutral
PRNewsWire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
PRNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Positive
The Motley Fool
1 week ago
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts.
Positive
The Motley Fool
1 week ago
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich
Three years ago, Summit Therapeutics (SMMT 1.26%) was a little-known small-cap biotech that few investors with an average tolerance for risk would have bothered to pay attention to at the time. However, the company's shares have skyrocketed by more than 2,000% since then.
Positive
The Motley Fool
1 week ago
3 Monster Stocks in the Making to Buy Right Now
Where can you find the next monster stocks? Check out the biotech space.
Neutral
PRNewsWire
1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Business Wire
2 weeks ago
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $SMMT--SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm.
Neutral
PRNewsWire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
PRNewsWire
3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Positive
Zacks Investment Research
3 weeks ago
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
Charts implemented using Lightweight Charts™